Phase I clinical trial utilizing gene therapy for limb girdle muscular dystrophy: alpha-, beta-, gamma-, or delta-sarcoglycan gene delivered with intramuscular instillations of adeno-associated vectors.
about
Manufacturing of recombinant adeno-associated viral vectors for clinical trialsNovel approaches to treat muscular dystrophies.Gene therapy for paediatric leukaemia.Good manufacturing practice production of self-complementary serotype 8 adeno-associated viral vector for a hemophilia B clinical trialPhase 2a study of ataluren-mediated dystrophin production in patients with nonsense mutation Duchenne muscular dystrophy.Gene therapy for muscular dystrophy - a review of promising progress.Safety of adeno-associated virus gene therapy vectors: a current evaluation.Gene therapy in orthopaedic surgery: the current status.Safety and feasibility of high-pressure transvenous limb perfusion with 0.9% saline in human muscular dystrophy.Gene therapy of liver diseases.High-Pressure Transvenous Perfusion of the Upper Extremity in Human Muscular Dystrophy: A Safety Study with 0.9% Saline.Safety and efficacy of factor IX gene transfer to skeletal muscle in murine and canine hemophilia B models by adeno-associated viral vector serotype 1.Progress and prospects: gene therapy clinical trials (part 1).Prospect of gene therapy for cardiomyopathy in hereditary muscular dystrophy.Enhancing transduction of the liver by adeno-associated viral vectors.The TLR9-MyD88 pathway is critical for adaptive immune responses to adeno-associated virus gene therapy vectors in mice.Gene transfer of arginine kinase to skeletal muscle using adeno-associated virus.AAV-directed muscular dystrophy gene therapy.Novel gene therapeutic strategies for the induction of tolerance in cornea transplantation.Evolving lessons on nanomaterial-coated viral vectors for local and systemic gene therapy.A novel gene expression control system and its use in stable, high-titer 293 cell-based adeno-associated virus packaging cell lines.An efficient rHSV-based complementation system for the production of multiple rAAV vector serotypes.Dystrophin Gene Replacement and Gene Repair Therapy for Duchenne Muscular Dystrophy in 2016: An Interview.Proteolytic mapping of the adeno-associated virus capsid.Limb-girdle muscular dystrophy type 2D gene therapy restores alpha-sarcoglycan and associated proteins.Immunity to adeno-associated virus serotype 2 delivered transgenes imparted by genetic predisposition to autoimmunity.
P2860
Q26750799-7DAF83E5-E8CA-4E19-BA59-2997F6A6F9C2Q34204364-8C948922-578E-4B69-9A4E-FC2CA05D5532Q34451905-920C49B3-B101-40F8-98BC-A2CAC750F80AQ34843808-921D511F-058F-4C39-89EB-F2886FEB59C8Q35069526-0D69DDE2-613A-4CEB-AFC7-E9D0838AE923Q35184730-397F0F20-D2A5-4132-9D2E-7E2C34AC6F46Q35194547-77B70081-B71D-40AB-80E9-8195EFC806BEQ35630146-A5582B7C-FA03-4AD9-B840-2F30FAC9999BQ35754170-99C27453-AE4E-4C2A-800B-B42312E9DE68Q35842662-2B194AE8-4306-4666-82DD-48D1E8134A3CQ36074105-435C2755-55DF-491B-B1CA-08C42CCF2795Q36438711-41D89175-CB10-4CD9-B526-59BD33E60921Q36957474-15F596BA-4B64-4678-B810-21C4B5DE3B81Q37021623-9F05ED3A-095C-45F5-8102-B96350C1B54CQ37042394-7BAD62B2-8277-4205-A0E9-7014291EC799Q37286686-160304E6-474D-4058-96D3-C8F670689D53Q37684597-44D121F9-43E3-4D94-9603-033D493FD6EBQ37687423-AB71A13D-61CD-47A3-8699-D39A7CE82AABQ37755334-CBC50231-08A9-4205-918E-EAB1D18F5056Q38848060-1E0E9638-ED7F-41B2-90B7-7F94613A1E8FQ39685433-802EC8C1-024E-405B-8136-FBAA2A5C2609Q39928784-3B21B08B-B86B-4F11-A3C6-31C9D18CD4BFQ42561764-F1965C48-36DC-4F6F-ACAC-816FA6103AA0Q42941986-135EDF6F-4F81-4CD2-AEAE-3F115D875DB1Q43268180-8E0BC40C-60F4-46AD-B87C-955EB3A77FADQ45698037-873A6460-B8C9-47A8-9B8B-385CFA0640A6
P2860
Phase I clinical trial utilizing gene therapy for limb girdle muscular dystrophy: alpha-, beta-, gamma-, or delta-sarcoglycan gene delivered with intramuscular instillations of adeno-associated vectors.
description
2000 nî lūn-bûn
@nan
2000年の論文
@ja
2000年学术文章
@wuu
2000年学术文章
@zh
2000年学术文章
@zh-cn
2000年学术文章
@zh-hans
2000年学术文章
@zh-my
2000年学术文章
@zh-sg
2000年學術文章
@yue
2000年學術文章
@zh-hant
name
Phase I clinical trial utilizi ...... s of adeno-associated vectors.
@en
Phase I clinical trial utilizi ...... s of adeno-associated vectors.
@nl
type
label
Phase I clinical trial utilizi ...... s of adeno-associated vectors.
@en
Phase I clinical trial utilizi ...... s of adeno-associated vectors.
@nl
prefLabel
Phase I clinical trial utilizi ...... s of adeno-associated vectors.
@en
Phase I clinical trial utilizi ...... s of adeno-associated vectors.
@nl
P2093
P1433
P1476
Phase I clinical trial utilizi ...... s of adeno-associated vectors.
@en
P2093
P304
P356
10.1089/10430340050015671
P577
2000-03-01T00:00:00Z